Prognostic Factors for Patients With a Large Number of Hepatocellular Carcinoma Nodules (original) (raw)
Tumor Response and Factors Affecting Survival of Using Sorafenib in Management of Advanced Hepatocellular Carcinoma
Eman Medhat
Biomedical Journal of Scientific & Technical Research, 2021
View PDFchevron_right
Evaluation of the Efficacy of Sorafenib on Overall Survival in Patients with Hepatocellular Carcinoma using FT Rate: A Devised Index
Nobuo Toda
Advances in Therapy
View PDFchevron_right
Evaluation of dose-efficacy of sorafenib and effect of transarterial chemoembolization in hepatocellular carcinoma patients: a retrospective study
Hsueh-chou Lai
BMC Gastroenterology, 2016
View PDFchevron_right
Investigating Up-to-Seven Criteria and APRI (AST Platelet Ratio) as Prognostic Factors in Intermediate-Stage Hepatocellular Carcinoma Patients Who Received Transarterial Chemoembolization
Nakarin Inmutto
Asian Pacific Journal of Cancer Prevention, 2022
View PDFchevron_right
Sorafenib with Transarterial Chemoembolization Achieves Improved Survival vs. Sorafenib Alone in Advanced Hepatocellular Carcinoma: A Nationwide Population-Based Cohort Study
郭集慶 Victor C Kok
Cancers (Basel), 2019
View PDFchevron_right
Comparative effectiveness of traditional chemoembolization with or without sorafenib for hepatocellular carcinoma
Ambuj Kumar
World Journal of Hepatology, 2013
View PDFchevron_right
Radiotherapy and Sorafenib in the Management of Patients with Hepatocellular Carcinoma Have Led to Improved Survival: A Single Center Experience
Salomon Stemmer
Journal of Cancer, 2016
View PDFchevron_right
Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization
Osamu Yokosuka
Oncology, 2014
View PDFchevron_right
TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON
Masatoshi Kudo
Radiology, 2016
View PDFchevron_right
Transarterial Chemoembolization (TACE) plus Sorafenib Versus TACE for Intermediate or Advanced Stage Hepatocellular Carcinoma: A Meta-Analysis
mahmoud elshawwaf
PLoS ONE, 2014
View PDFchevron_right
Prospective, randomized, double-blind, multi-center, Phase III clinical study on transarterial chemoembolization (TACE) combined with Sorafenib®versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation – HeiLivCa [ISRCTN24081794]
Vikram Haridas
BMC Cancer, 2008
View PDFchevron_right
Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial Chemoembolization and Poor Prognosis
Kazuhiro Katayama
Journal of Clinical Medicine Research, 2018
View PDFchevron_right
Exploring the efficacy and safety of single-agent sorafenib in a cohort of Italian patients with hepatocellular carcinoma
Daniele Santini
Expert Review of Anticancer Therapy, 2012
View PDFchevron_right
Transarterial chemoembolization versus sorafenib in patients with hepatocellular carcinoma and extrahepatic disease
Arndt Weinmann
United European Gastroenterology Journal, 2018
View PDFchevron_right
TACE performed in patients with a single nodule of Hepatocellular Carcinoma
Rita Golfieri
2014
View PDFchevron_right
Factors affecting tumor response to transarterial chemoembolization (TACE) therapy in patient with hepatocellular carcinoma (HCC)
nikmatia latief
Journal of thee Medical Sciences (Berkala Ilmu Kedokteran), 2020
View PDFchevron_right
Continuous Administration of Sorafenib in Combination with Transarterial Chemoembolization in Patients with Hepatocellular Carcinoma: Results of a Phase I Study
Beat Helbling, Daniel Candinas
The Oncologist, 2010
View PDFchevron_right
Factors predictive of 5-year survival after transarterial chemoembolization for inoperable hepatocellular carcinoma
Ronnie Poon
British Journal of Surgery, 2003
View PDFchevron_right
Exploratory Analysis to Identify Candidates Benefitting from Combination Therapy of Transarterial Chemoembolization and Sorafenib for First-Line Treatment of Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Observational Study
Evangelos Karfopoulos
Liver Cancer, 2020
View PDFchevron_right
Transarterial chemoembolization in very early and early-stage hepatocellular carcinoma patients excluded from curative treatment: A prospective cohort study
Michele Bertoni
European Journal of Radiology, 2012
View PDFchevron_right
Transarterial Chemoembolization Plus Sorafenib: A Sequential Therapeutic Scheme for HCV-Related Intermediate-Stage Hepatocellular Carcinoma: A Randomized Clinical Trial
Vincenza Conteduca
The Oncologist, 2012
View PDFchevron_right
Transarterial Chemoembolization (TACE) Plus Sorafenib Compared to TACE Alone in Transplant Recipients with Hepatocellular Carcinoma: An Institution Experience
Edward A Graviss
Cancers
View PDFchevron_right
Transarterial chemoembolization for the treatment of hepatocellular carcinoma: A single center experience including 221 patients
Nelly H Alieldin
Journal of the Egyptian National Cancer Institute, 2013
View PDFchevron_right
Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience
Patrizia Zavattari
Gastrointestinal Tumors
View PDFchevron_right
Final Results of TACTICS: A Randomized, Prospective Trial Comparing Transarterial Chemoembolization Plus Sorafenib to Transarterial Chemoembolization Alone in Patients with Unresectable Hepatocellular Carcinoma
Kiwamu Okita
Liver Cancer
View PDFchevron_right
Combination of TACE and Sorafenib Improves Outcomes in BCLC Stages B/C of Hepatocellular Carcinoma: A Single Centre Experience
Joy Varghese
Annals of Hepatology, 2017
View PDFchevron_right
The combination of sorafenib with transarterial chemoembolisation for hepatocellular carcinoma
Roniel Cabrera
Alimentary Pharmacology & Therapeutics, 2011
View PDFchevron_right
Transarterial Chemoembolization for Hepatocellular Carcinoma in Clinical Practice: Temporal Trends and Survival Outcomes of an Iterative Treatment
Eugenio Caturelli
Frontiers in Oncology, 2022
View PDFchevron_right
Clinical significance of the best response during repeated transarterial chemoembolization in the treatment of hepatocellular carcinoma
Kang Kim
Journal of Hepatology, 2014
View PDFchevron_right
HCC: Achieving Complete Response in a Patient After Liver Transplantation, Metastatic Hepatocellular Carcinoma with Sorafenib Treatment and Radiotherapy Continued with Follow-up
Piyush Vyas
Novel Approaches in Cancer Study, 2019
View PDFchevron_right
Long-term complete response of advanced hepatocellular carcinoma treated with multidisciplinary therapy including reduced dose of sorafenib: case report and review of the literature
Yuta Abe
World journal of surgical oncology, 2015
View PDFchevron_right
CT volume of enhancement of disease (VED) can predict the early response to treatment and overall survival in patients with advanced HCC treated with sorafenib
Claudia Campani
European Radiology, 2020
View PDFchevron_right
Field-Practice Study of Sorafenib Therapy for Hepatocellular Carcinoma: A Prospective Multicenter Study in Italy
Ambulatorio Fegato
View PDFchevron_right